ReviewFrontiers in cell and developmental biology2025
Therapeutic effects of mesenchymal stromal cells transplantation in animal models of chronic obstructive pulmonary disease: a systematic review and meta-analysis of emphysema and lung inflammation models.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic obstructive pulmonary disease (COPD) presents core pathological changes that current medications cannot reverse. Mesenchymal stromal cell (MSC) transplantation has shown therapeutic potential in preclinical studies; however, significant heterogeneity and inconsistency exist in animal experiments simulating key COPD pathologies (such as emphysema and inflammation) based on acute injury models. We aim to systematically evaluate the efficacy of MSC transplantation in animal models simulating COPD pathology through a meta-analysis and to explore the impact of key strategies such as administration routes and dosages on efficacy. Methods: A systematic search was performed in PubMed, Web of Science, Embase, and Scopus databases (up to 1 July 2025) to identify randomized controlled trials (RCTs) involving MSC transplantation in animal models of simulated COPD pathology. Risk of bias was assessed using the SYRCLE tool, and meta-analysis was conducted using R software. Results: A total of 40 studies were included. The meta-analysis revealed that MSC transplantation significantly improved alveolar structural damage compared to control groups (MLI: SMD = -2.84, 95% CI: 3.22 to -2.45), increased anti-inflammatory IL-10 levels (SMD = 6.54, 95% CI: 2.08-11.00), reduced pro-inflammatory TNF-α levels (SMD = -1.61, 95% CI: 2.72 to -0.5), and significantly inhibited pulmonary tissue cell apoptosis (SMD = -4.06, 95% CI: 5.71 to -2.41). Subgroup analysis showed that intratracheal transplantation was more effective than intravenous transplantation in improving MLI, enhancing IL-10 levels, and reducing apoptosis. Moreover, the therapeutic effects were dose-dependent, with higher doses (≥5 × 10 Conclusion: MSC transplantation exerts multiple therapeutic effects by alleviating emphysema, regulating inflammatory balance, and inhibiting cell apoptosis. The study further identifies intratracheal delivery and higher cell dosages as promising optimization strategies for MSC transplantation. These findings provide critical references for the standardized design of future preclinical studies and the selection of parameters for subsequent clinical trials, while the differences in disease progression between animal models and human conditions remain key factors to consider for future clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.